尿促卵泡素(Urofollitropin (Serono)) - 药物靶点：FSHR_在研适应症：女性不育伴无排卵_专利_临床

概要

基本信息

药物类型

激素

别名

Fertinex、Fertinorm HP、Follitropin human

+ [7]

靶点

FSHR

作用机制

FSHR激动剂(卵泡刺激素受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

女性不育伴无排卵

非在研适应症-

原研机构

Merck Serono SA

在研机构

Ferring GmbHFerring Holding SA香港辉凌制药有限公司北京代表处

+ [1]

非在研机构

Ferring Pharmaceuticals SA

EMD Serono, Inc.

最高研发阶段临床3期

首次获批日期

美国 (1986-09-18),

不孕

最高研发阶段(中国)临床3期

特殊审评孤儿药 (美国)

登录后查看时间轴

序列信息

Sequence Code 3246α

Sequence Code 3253α

关联

19

项与尿促卵泡素相关的临床试验

NCT05362799 / Unknown status临床4期IIT

Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

The aim of this study will be to compare between 4 different induction protocols in women who:
Failed to achieve ovulation after clomiphene citrate treatment at a dose of 150mg daily (if the patient can tolerate this dose) for 5 days for 3 cycles or only 100 mg daily for the same duration (if she can't tolerate higher dose)
Failed to achieve pregnancy after 3 cycles of ultrasound indicated ovulation with clomiphene citrate treatment at a dose of 100mg or 150mg daily.
All induction protocols will be carried out in non-IVF cycles, and continued for 3 cycles or until pregnancy whichever will be earlier.

开始日期2022-06-01

申办/合作机构

Menoufia University

EUCTR2016-004034-14-IT / Unknown status临床2/3期IIT

Randomized controlled phase IIb-III clinical trial to assess the effectiveness of different regimens with u-FSH in the infertile male - UFO – UROFOLLITROPIN IN OLIGOZOOSPERMIA

开始日期2018-10-11

申办/合作机构-

NCT02544191 / Unknown status临床2期IIT

GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia: A Single-center Prospective Study in China

Preliminary reports showed that hormonal treatment may improve the chance of retrieving viable testicular sperm from men with NOA. It was generally believed that gonadotrophin treatment would be ineffective in the presence of high plasma levels of endogenous gonadotrophin.The purpose of this study is to determine whether GnRHa(gonadotropin-releasing hormone agonist) combined with hCG(human chorionic gonadotropin) and hMG(human menopausal gonadotropin) are effective in the treatment of non-obstructive azoospermia.

开始日期2015-12-01

申办/合作机构

南京大学医学院附属金陵医院

100 项与尿促卵泡素相关的临床结果

登录后查看更多信息

100 项与尿促卵泡素相关的转化医学

登录后查看更多信息

100 项与尿促卵泡素相关的专利（医药）

登录后查看更多信息

155

项与尿促卵泡素相关的文献（医药）

2023-09-01·Zhonghua nan ke xue = National journal of andrology

[Clinical efficacy of Xuanju compound capsule combined with urofollitropin in the treatment of patients with idiopathic oligoasthenozoospermia].

Article

作者: Chen, Li-Sha ; Yu, Yue-Xin ; Shi, Sheng-Jia ; Zhao, Ying-Ying ; Wei, Wei

OBJECTIVETo evaluate the therapeutic effects of Xuanju compound capsule combined with urofollitropin (uFSH) in the treatment of idiopathic oligoasthenozoospermia.METHODSFrom June 2022 to June 2023, patients with idiopathic oligoastheospermia were enrolled in this study, and divided into trail group (Xuanju compound capsule combined with urofollitropin tablets, n=53) and control group (urofollitropin tablets, n=61) according to the difference in treatment. Treatment methods: Xuanju compound capsule, 3 pills, three times a day; Urofollitropin, 75IU, one times three day. The curses of treatments for control group and trail group is 12 weeks. In order to evaluate the therapeutic effects of control group and trial group, semen volume, sperm concentration, progressive sperm ratio (PR), peripheral serum sex hormone, liver functions were analyzed before and after treatment for two times.RESULTSCompared with the baseline, the semen volume and liver function were not significantly changed after the treatment in control group and trial group. However, sperm concentration, PR, testosterone (T) levels, follicle stimulating hormone (FSH) levels, and luteinizing hormone (LH) levels were significantly unregulated after the treatment in control group and trial group. More importantly, compared to control group, sperm concentration, PR, T leves, FSH levels, LH levels, and T/E2 ratio of trial group were further enhanced after the treatment, which were statistically significant (P < 0.05).CONCLUSIONSXuanju compound capsule combined with urofollitropin tablets could significantly improve the semen quality, up-regulate the testosterone levels and T/E2 ratio in patients with idiopathic oligoasthenozoospermia.

2023-01-01·Gynecologic and Obstetric Investigation

Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study

Article

作者: Allignol, Arthur ; Bühler, Klaus ; Schertz, Joan ; Longobardi, Salvatore ; Hubbard, Julie ; Verpillat, Patrice ; Fischer, Robert ; Strezsak, Valerie ; Lispi, Monica

Objectives: The aim of the study was to evaluate dosing of recombinant human luteinizing hormone (r-hLH) or human menopausal gonadotrophin (hMG)-derived medications with LH activity in ovarian stimulation (OS) cycles for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). Design: A non-interventional study was performed to analyse data from the German RecDate database (January 2007–December 2011). Participants/Materials, Setting, Methods: Starting/total r-hLH/hMG dose, OS duration/cycle number, r-hLH/hMG initiation day (first day of administration), and population/cycle characteristics were assessed in women (≥18 years) undergoing OS for IVF/ICSI using r-hLH or hMG-derived medications (excluding corifollitropin alfa, clomiphene citrate, letrozole, mini/micro-dose human chorionic gonadotrophin, and urofollitropin alone). Data were summarized descriptively. Results: 67,858 identified cycles utilized medications containing r-hLH (10,749), hMG (56,432), or both (677). Mean (standard deviation) OS duration with r-hLH and hMG was 10.1 (4.43) and 9.8 (6.16) days, respectively. Median (25th–75th percentile) r-hLH starting dose (75.0 [75.0–150.0] IU) was consistent across patients regardless of age, infertility diagnosis, or gonadotrophin-releasing hormone (GnRH) protocol. Median (25th–75th percentile) hMG-derived LH activity starting dose was 225.0 (150.0–300.0) IU, regardless of GnRH protocol, but was lower in women aged <35 years and those with ovulation disorders/polycystic ovary syndrome. Median (25th–75th percentile) total dose for r-hLH (750.0 [337.5–1,125.0] IU) and hMG-derived LH activity (1,575.0 [750.0–2,625.0] IU) varied according to patients’ age, infertility diagnosis, cycle number, and r-hLH/hMG initiation day. GnRH antagonist use resulted in a numerically higher median total hMG-derived LH activity dose than GnRH agonist use. Limitations: The data used in this study were taken from electronic medical records relating to a specific timeframe (2007–2011) and therefore may not accurately reflect current clinical practice; however, it is likely that the differences between the two compounds would be maintained. Additionally, secondary data sources may suffer from uniformity and quality issues. Conclusions: The standard of care for OS cycles is described with respect to IVF/ICSI treatment including an LH component in Germany during the specified timeframe.

2021-10-01·Carbohydrate Polymers1区 · 化学

Dry cultivation and cultivar affect starch synthesis and traits to define rice grain quality in various panicle parts

1区 · 化学

Article

作者: Jiang, Yang ; Chen, Zongkui ; Cai, Mingli ; Du, Yunfeng ; Li, Ping ; Cao, Cougui

A pot experiment was conducted to explore the effects of high-quality (Huanghuazhan, HH), drought-resistant (IR, IRAT109) and drought-susceptible cultivars (ZS, Zhenshan97) under flooding irrigation and dry cultivation (D) on the starch accumulation and synthesis, physicochemical traits of starch granules and rice grain quality at the upper (U) and lower panicle. Under D treatment, IR and ZS had lower rice quality, especially the appearance and cooking quality. DHH-U had the highest appearance, nutritional and cooking quality among all cultivars under D treatment, which could be ascribed to the synthesis of more short-branch chain amylopectin and correspondingly higher starch granule tightness. DHH-U also maintained ordered carbohydrate structure, crystalline regions, and many hydrophilic and hydrophobic functional groups in starch granules before pasting. It could prevent the polymerization of small molecules to avoid the formation of macromolecules after pasting. Overall, these findings may facilitate the improvement of grain quality in rice dry cultivation.

100 项与尿促卵泡素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06269	尿促卵泡素	G03GA04	DB00094

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
女性不育伴无排卵	临床3期	中国	Ferring GmbH	2013-10-17
女性不育伴无排卵	临床3期	中国	Ferring Holding SA	2013-10-17
女性不育伴无排卵	临床3期	中国	香港辉凌制药有限公司北京代表处	2013-10-17
女性不育伴无排卵	临床3期	中国	Ferring Arzneimittel Gmbh	2013-10-17
女性不孕症	药物发现	中国	Ferring Pharmaceuticals SA	2014-06-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01969201 (FAST, CTgov)	临床4期	不孕	710	Urofollitrophin (Fostimon®)	觸淵製網醖顧夢願獵艱(壓衊範選遞壓廠壓繭壓) = 壓窪糧糧襯衊膚範觸顧醖窪鏇繭廠衊鏇餘蓋鹽 (構製選艱築廠憲衊積積, 蓋窪鹹淵餘製衊鏇鬱選 ~ 願夢餘憲鹽鏇構艱憲構) 更多	-	2019-10-09
				Follitrophin alpha (Gonal-F®)	觸淵製網醖顧夢願獵艱(壓衊範選遞壓廠壓繭壓) = 積選顧繭繭築衊網憲齋醖窪鏇繭廠衊鏇餘蓋鹽 (構製選艱築廠憲衊積積, 製艱鬱鑰蓋廠鹹夢願鹹 ~ 簾鑰糧鏇願衊繭構範衊) 更多
NCT01921166 (Diminished Ovarian Reserve, CTgov)	临床4期	不孕	23	Menopur+Clomid+Bravelle+Follistim+Gonal f (Clomiphene Plus Gonadotropins)	積淵鹹夢選淵蓋憲鏇襯(範積壓築築鹽遞鏇壓淵) = 壓艱獵遞鬱膚蓋鬱鏇襯艱憲艱廠鹽顧選鹹憲醖 (鹽鏇遞遞簾艱壓繭鬱窪, 夢淵鹽廠繭夢夢獵鹹蓋 ~ 網鏇製觸繭餘鹹鬱鹹衊) 更多	-	2018-02-23
				Leuprolide flare (Leuprolide Flare)	積淵鹹夢選淵蓋憲鏇襯(範積壓築築鹽遞鏇壓淵) = 簾鹽衊顧鹽衊蓋獵製鬱艱憲艱廠鹽顧選鹹憲醖 (鹽鏇遞遞簾艱壓繭鬱窪, 醖齋鏇顧繭鏇膚構積衊 ~ 鹽範選鏇襯製淵獵獵鑰) 更多
NCT01417195 (COMBINE, CTgov)	临床4期	不孕	122	Menopur+Bravelle (Menopur and Bravelle Combination)	(選遞壓衊壓壓積鏇製遞) = 獵蓋艱餘觸鑰膚鹹憲鹹衊廠膚襯醖顧壓願衊鏇 (鑰遞積衊膚製製構遞糧, 構鹹觸鏇遞選製鑰壓憲 ~ 築鹽繭餘夢築齋齋築蓋) 更多	-	2014-04-24
				Menopur (Menopur Alone)	(選遞壓衊壓壓積鏇製遞) = 餘壓襯夢夢齋膚願鏇襯衊廠膚襯醖顧壓願衊鏇 (鑰遞積衊膚製製構遞糧, 壓積蓋遞窪鑰壓蓋糧構 ~ 衊壓範繭蓋顧齋鏇鑰淵) 更多